Abstract:In the realm of enzymology, Carbonic anhydrase (CA) emerges as a pivotal protagonist orchestrating the rapid conversion of carbon dioxide and water into bicarbonate ions and hydrogen ions, respectively. Carbonic anhydrase inhibitors (CAIs) are the class of drugs that target various isoforms of the enzyme, and these inhibitors play a crucial role in the treatment and management of multiple diseases such as cancer, glaucoma, high altitude sickness, rheumatoid arthritis, obesity, epilepsy, and sleep apnea. Several structural classes of CAIs developed till date possess unique architects of the pharmacophoric requirements around the central core moiety for the selective targeting of various isoforms of the CA. Recent advancements in drug design and development, along with technologies that aid in structure determination, have led to the development of several isoform-selective inhibitors of CA enzymes. However, their therapeutic utility has still not been fulfilled due to the lack of desired potency, isoform selectivity, and pharmacokinetic properties. This review covers the most recent approaches used by different researchers, which are concerned with the development of isoform-selective carbonic anhydrase inhibitors belonging to distinct structural classes like sulphonamides, carbazoles, selenols, coumarin, organotelluride, topiramate, thiophene, triazole, uracil-modified benzylic amines, and thiourea etc. In addition, their structure–activity relationships, biological evaluation, and in silico studies as well as the forthcoming avenues of advancements have been discussed. This review serves as a valuable resource for developing potent and efficacious CAIs with remarkable therapeutic implications, offering insights into their potency, specificity, and potential clinical applications.

Sulfonamides and their isosters as carbonic anhydrase inhibitors

Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes

Structure-based drug discovery of carbonic anhydrase inhibitors

Non-classical inhibition of carbonic anhydrase

Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design

Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides

Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives

Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino− polycarboxylate tails and of their metal complexes …

Carbonic anhydrase inhibitors drug design

Advances in structure-based drug discovery of carbonic anhydrase inhibitors

Secondary/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II

Development of sulfonamide carbonic anhydrase inhibitors

Sulfonamide inhibitors of bacterial carbonic anhydrases

Therapeutic potential of sulfamides as enzyme inhibitors

Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors

Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route

Carbonic anhydrases: Moiety appended derivatives, medicinal and pharmacological implications

Drug interactions of carbonic anhydrase inhibitors and activators

Carbonic anhydrase inhibitors—Part 29 1: Interaction of isozymes I, II and IV with benzolamide-like derivatives

Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?

Novel sulfonamide-phosphonate conjugates as carbonic anhydrase isozymes inhibitors